I am not an expert in this field, but I am very interested and have researched to find an answer. I received some assistance from tlooto.com for this response. Could you please review the response below to see if it is correct?

To practice radiolabeling techniques before using expensive antibodies like pembrolizumab and nivolumab, it is advisable to utilize a model antibody that is cost-effective and well-documented. Trastuzumab is an excellent candidate for this purpose due to its widespread availability and extensive use in radiolabeling studies, particularly with isotopes like 89Zr and 64Cu [1][2][3].

Trastuzumab has been effectively labeled using various chelators such as desferrioxamine (DFO) for 89Zr radiolabeling, achieving high radiochemical yields (RCY) and specific activities while maintaining immunoreactivity and favorable in vivo biodistribution profiles [1][2]. The optimized conditions for radiolabeling trastuzumab include using chelexed PBS as buffer, minimal buffer volume, and avoiding radioprotectants to maximize specific activity and preserve immunoreactivity [2]. This makes trastuzumab a valuable model for practicing the conjugation, radiolabeling, purification, and quality control (QC) processes.

Furthermore, trastuzumab has been used in comprehensive radiolabeling studies, providing detailed protocols and insights into the effects of various conjugation and labeling conditions on the final product's performance [1][2]. By following these established protocols, you can fine-tune your radiolabeling techniques without the high cost associated with therapeutic antibodies like pembrolizumab and nivolumab.

In summary, using trastuzumab as a model antibody allows you to optimize your radiolabeling procedures efficiently and cost-effectively, ensuring that you are well-prepared to work with more expensive antibodies. This approach minimizes waste and cost while providing a robust and reproducible methodology for your radiolabeling experiments.

Reference

[1] Tran, V., Bouleau, A., Nozach, H., Richard, M., Chevaleyre, C., Dubois, S., Kereselidze, D., Kuhnast, B., Evans, M., Specklin, S., & Truillet, C. (2022). Impact of Radiolabeling Strategies on the Pharmacokinetics and Distribution of an Anti-PD-L1 PET Ligand.. Molecular pharmaceutics.

[2] Uccelli, L., Martini, P., Pasquali, M., & Boschi, A. (2017). Monoclonal Antibodies Radiolabeling with Rhenium-188 for Radioimmunotherapy. BioMed Research International, 2017.

[3] Maguire, W., McDevitt, M., Smith-Jones, P., & Scheinberg, D. (2014). Efficient 1-Step Radiolabeling of Monoclonal Antibodies to High Specific Activity with 225Ac for α-Particle Radioimmunotherapy of Cancer. The Journal of Nuclear Medicine, 55, 1492 - 1498.

Park Sowon thank you for your help.

I'll take a look

Dear Laetitia Mistico

check the abinvivo catalogue

they sell a lot of differrent mabs with relativelly good prices.

best

Manuele

Manuele Martinelli thank you so much.

My best reagrds

Laetitia